Intrexon Organizes Around New Synthetic Biology Markets
5/9/2013
Nine Collaborations Underway, Company Aligns to Accelerate Business Development in Health, Food, Energy and Environment   Germantown, Maryland, May 9, 2013 – Intrexon Corporation, a...
Soligenix and Intrexon Pursue Melioidosis Therapy Through Worldwide Exclusive Collaboration
5/1/2013
Soligenix to Expand Biodefense and Infectious Disease Product Pipeline Princeton, NJ and Germantown, MD – May 1, 2013 – Soligenix, Inc. (OTCQB: SNGX), a clinical stage...
Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
5/1/2013
Germantown, Maryland, May 1, 2013 – Intrexon Corporation, a next generation synthetic biology company, today announced that it has closed a Series F preferred investment round of $150 million,...
AmpliPhi Establishes Collaboration with Intrexon
4/16/2013
Combined Expertise to Create New Generation of Bacteriophage-Based Therapeutics For Antibiotic Resistant Infections Richmond, VA, and Germantown, MD, April 16, 2013 – AmpliPhi BioSciences...
ZIOPHARM Presents Preclinical Data Supporting DNA-based IL-12 Therapy for Breast Cancer
4/9/2013
Immunotherapeutic Strategy Results Presented at AACR 2013 Annual Meeting   NEW YORK, NY – April 9, 2013 – ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company...
ZIOPHARM Oncology Initiates Phase 2 Study of Ad-RTS IL-12 and Palifosfamide Combination for Treatment of Advanced Breast Cancer
3/11/2013
NEW YORK, NY – March 11, 2013 – ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today...
Intrexon and AquaBounty to Collaborate on Leveraging Synthetic Biology to Increase Productivity Across the Aquaculture Arena
2/15/2013
-Exclusive Channel Collaboration Driven by Need to Meet Growing World Food Demand -Intrexon Proposes to invest up to $6.0 million in AquaBounty   Germantown, MD and Maynard, MA –...
Intrexon Completes Mandatory Tender Offer for AquaBounty Technologies Shares
1/7/2013
Blacksburg, Virginia – January 7, 2013 - Intrexon Corporation, a synthetic biology company that utilizes its proprietary technologies to provide control over cellular function, today announced...
Sanford-Burnham Medical Research Institute and Intrexon Corporation Establish Collaboration to Accelerate Stem Cell Research
1/3/2013
Combines Sanford-Burnham’s renowned scientific team and Intrexon’s proprietary discovery platforms to accelerate human induced pluripotent stem cell (iPSC) research   LA JOLLA,...
Synthetic Biologics and Intrexon Corporation Initiate Development of Monoclonal Antibodies for Whooping Cough (Pertussis)
12/20/2012
-- The University of Texas at Austin to Join in Pertussis Research Efforts -- Rockville, MD, and San Francisco, CA, December 20, 2012 – Synthetic Biologics, Inc. (NYSE MKT: SYN), a...
ZIOPHARM Oncology Presents Systemic, DNA/Cell Plasmid Therapy Showing Long-Term Persistence and Anti-Tumor Effects at EORTC-NCI-AACR Meeting
11/7/2012
NEW YORK, NY – November 7, 2012 – ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced...
Intrexon to Acquire 48% Stake in AquaBounty Technologies
11/1/2012
- Utilizing Biotechnology to Improve Productivity in Aquaculture Blacksburg, Virginia – October 31, 2012 - Intrexon Corporation, a synthetic biology company that utilizes its proprietary...
ZIOPHARM Oncology Announces Compelling Clinical Activity in Phase 1 Study of Ad-RTS IL-12 in Advanced Melanoma and Dosing of First Patient in Phase 2 Study
10/25/2012
NEW YORK, NY – October 25, 2012 – ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today...
Fibrocell Science, Inc. Announces $45 Million Private Placement and Enters Strategic Collaboration with Intrexon
10/8/2012
-- Proceeds to Support Commercial Launch of LAVIV and Expand Development of their Proprietary Fibroblast Platform -- Strategic Collaboration with Intrexon to Advance Development and...
Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
9/18/2012
-- Acinetobacter Infections Pose Growing Concern in Hospitals, and in Military and Natural Disaster Trauma Centers -- Company Engages Former Pfizer/Wyeth Global Infectious Disease Pharmaceutical...
Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
8/8/2012
Collaboration Harnesses Monoclonal Antibodies to Address Unmet Medical Needs Joint Conference Call Scheduled for Today, Wednesday, August 8, 2012 at 5:00pm(ET)/2:00pm(PT) Rockville, MD, and...
BioLife Cell Bank and Intrexon Corporation Establish Worldwide Exclusive Collaboration for Spinal Muscular Atrophy (SMA)
8/2/2012
Dallas, Texas & Germantown, Maryland - August 2, 2012 - BioLife Cell Bank, Inc., the leader in cryogenic storage of adipose (fat) tissue and adult mesenchymal stem and regenerative cells, and...
Oragenics and Intrexon Announce Worldwide Exclusive Collaboration for Lantibiotics
6/6/2012
Oragenics and Intrexon Announce Worldwide Exclusive Collaboration for Lantibiotics, a Novel Class of Broad Spectrum Antibiotics For Immediate Release Tampa, FL, & Germantown, MD, June 6,...
Experienced Life Sciences Executive to Join Intrexon as Chief Operating Officer
12/5/2011
Krish S. Krishnan, M.S., M.B.A., appointed Chief Operating Officer Blacksburg, Virginia, December 5, 2011. Intrexon Corporation, a privately held synthetic biology engineering company, today...
Prior CEOs of Monsanto and Pfizer join Intrexon Board of Directors
11/28/2011
Blacksburg, Virginia, November 28, 2011. Intrexon Corporation, a privately held synthetic biology engineering company, today announced the appointments of Robert B. Shapiro and Jeffrey B. Kindler...
Adeona and Intrexon Announce Worldwide Exclusive Collaboration for PAH Therapy
11/21/2011
Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension For Immediate Release Ann Arbor, MI,...
Intrexon Acquires Immunologix, Inc.
10/24/2011
Novel fully human antibody development group joins top synthetic biology company Blacksburg, Virginia, October 24, 2011. Intrexon Corporation, a privately held synthetic biology company, today...
Intrexon Launches Cell Engineering Unit
10/11/2011
Blacksburg, Virginia, October 11, 2011. Intrexon Corporation, a privately held synthetic biology company, today announced the formation and launch of its Cell Engineering Unit (CEU) in San Diego, CA. The new unit will be under the leadership of the company’s Chief Science Officer and Founder, Thomas D. Reed, Ph.D. As part of the launch, Intrexon simultaneously announced the acquisition of GT Life Sciences, Inc. and the purchase of assets comprising the LEAP cell-processing platform from Cyntellect, Inc. The two transactions provide the foundational technology, facilities, exclusive IP portfolios, and team for the new scientific unit. Terms of the transactions were not disclosed.
FierceBiotech Names Intrexon a 2011 Fierce 15 Biotech
9/6/2011
Blacksburg, Virginia, September 6, 2011. Intrexon Corporation, a privately held synthetic biology company, today announced being named by FierceBiotech as one of 2011’s Fierce 15, designating...
ZIOPHARM Oncology Announces First Patient Dosed in Phase I Study of ZIN ATI-001 in Advanced Melanoma
8/30/2011
NEW YORK, NY (August 30, 2011) — ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced that the first patient has been dosed in a Phase 1 clinical study of ZIN ATI-001, a novel DNA-based...
ZIOPHARM Oncology to Host Analyst & Institutional Investor Meeting on June 23, 2011
6/16/2011
NEW YORK--(BUSINESS WIRE)-- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today that the Company will host an analyst and institutional investor meeting on Thursday, June 23, 2011, from 5:00 to 6:30 PM Eastern Time in New York City.
ZIOPHARM Oncology Announces Acceptance of Investigational New Drug Application for ZIN ATI-001 (Ad-RTS-IL-12), a Novel DNA-Based Oncology Therapeutic Candidate
6/10/2011
NEW YORK, NY (June 10, 2011) — ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that the U.S. Food & Drug Administration (FDA) has accepted the Company’s investigational new drug (IND) application to begin clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate also known as Ad-RTS-IL-12 + AL (INXN 2001/1001), in oncology. When initiated, the Phase I study will evaluate safety in addition to immunological and biological effects of the therapeutic candidate in patients with melanoma. ZIN ATI-001 is the second clinical oncology product candidate from the ZIOPHARM-Intrexon Corporation exclusive synthetic biology channel partnership.
ZIOPHARM Announces Initial Positive Data Presented at 2011 ASCO Annual Meeting from First-Ever Treatment Demonstrating Small Molecule-Controlled Production of Anticancer Protein in Humans
6/6/2011
CHICAGO, IL (June 6, 2011) – ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Douglas J. Schwartzentruber, MD, FACS, of the Indiana University Health Goshen Center for Cancer Care, presented initial positive clinical results from the first-ever treatment demonstrating control over transgene encoding of a therapeutic anticancer protein in humans using a small molecule activator ligand. These results were presented at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 3 – 7, in Chicago, IL.
Halozyme and Intrexon Announce Collaboration to Develop First Subcutaneous Recombinant Alpha 1-Antitrypsin Replacement Therapy
6/6/2011
SAN DIEGO and FOSTER CITY, Calif., June 6, 2011 — Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Intrexon Corporation, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 (recombinant human hyaluronidase) in the development of a subcutaneous (under the skin) injectable formulation of Intrexon Corporation’s recombinant human alpha 1-antitrypsin (rHuA1AT). Under terms of the agreement, Halozyme may receive up to $63 million, commencing with an upfront payment of $9 million and total potential future milestone payments of $54 million dependent upon the achievement of clinical and regulatory targets, plus up to 11% royalty on future sales of the combination of rHuA1AT with rHuPH20. The license provides Intrexon Corporation, a next generation synthetic biology company, with exclusivity to alpha 1-antitrypsin, for the indications resulting from A1AT deficiency. Additional terms of the transaction have not been disclosed.
Intrexon Corporation Raises $100 Million for Synthetic Biology Initiatives
5/31/2011
Blacksburg, Virginia, May 31, 2011. – Intrexon Corporation, a next generation synthetic biology company, today announced that it has closed a Series E preferred investment round of $100 million, bringing the company’s total capital raised to more than $259 million. New investors took the majority of the round while existing investors, including Randal J Kirk, Intrexon’s Chairman and CEO, and Third Security, LLC, took the remainder. Perella Weinberg Partners acted as Intrexon’s exclusive financial advisor and placement agent.
ZIOPHARM and Intrexon Announce Preclinical Study Results at 2011 ASGCT Meeting from Controlled In Vivo Expression of Genes with Broad and Potent Antitumor Activity
5/20/2011
SEATTLE, WA (May 20, 2011) – ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), and Intrexon Corporation announced today that results from two preclinical studies examining the tightly controlled, intra-tumoral expression of a novel protein, interleukin-12 (IL-12), in melanoma, colon, lung, leukemia, breast and pancreatic cancer models in mice, were presented at the 2011 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), held May 18 – 21 in Seattle, Washington.
ZIOPHARM Oncology Files Investigational New Drug Application for Ad-RTS-IL-12, a Novel DNA-Based Oncology Therapeutic Candidate
5/16/2011
NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12 (INXN 2001/1001), a novel DNA-based therapeutic candidate. When initiated, the Phase I study will evaluate safety in addition to immunological and biological effects of the therapeutic candidate in patients with melanoma. Ad-RTS-IL12 is the second clinical oncology product candidate from the ZIOPHARM/Intrexon Corporation’s exclusive, synthetic biology channel partnership.
Intrexon Launches Animal Science Division
4/27/2011
Germantown, Maryland, April 27, 2011. Intrexon Corporation, a next generation synthetic biology company, today announced the launch of its Animal Science Division and appointment of Thomas R. Kasser, Ph.D. as Division President and a Senior Vice President of the Corporation. The Division is located in Germantown, Maryland, and focused on pioneering novel approaches that protect and enhance the health of companion and production animals, improve production animal efficiency, and enable more relevant animal research models.
Intrexon Acquires Neugenesis Corporation and Establishes Industrial Products Location
4/21/2011
Burlingame, CA, April 21, 2011. Intrexon Corporation, a next generation synthetic biology company, today announced the acquisition of Neugenesis Corporation, a California-based company that has developed recombinant technologies and production systems related to Neurospora crassa, an exceptionally versatile fungal organism capable of producing a wide spectrum of proteins and metabolites of commercial interest. Intrexon also announced that the former Neugenesis facility is now the headquarters for Intrexon’s Industrial Products Division.
Intrexon Corporation to Present at J.P. Morgan Healthcare Conference
1/7/2011
Blacksburg, VA, January 07, 2011. — Intrexon Corporation today announced that Randal J. Kirk, Chairman and Chief Executive Officer, will be presenting a corporate overview at the 29th Annual J.P. Morgan Healthcare Conference. Intrexon's presentation will take place at 4:00 p.m. PST on Monday, January 10, 2011 at The Westin St. Francis hotel, San Francisco, CA.
ZIOPHARM Oncology and Intrexon Announce Worldwide Partnership for Synthetic Biology DNA-based Oncology Therapeutics
1/6/2011
NEW YORK, NY and GERMANTOWN, MD (January 6, 2011) – ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a small molecule late-stage oncology drug development company, and Intrexon Corporation, a next generation synthetic biology company, announced today a global exclusive channel partnership in oncology where ZIOPHARM will develop and commercialize DNA-based therapeutics using Intrexon’s UltraVector® Technology. Under the partnership, ZIOPHARM will utilize Intrexon’s advanced transgene engineering platform for the controlled and precise cellular production of anti-cancer effectors. ZIOPHARM will have rights to Intrexon’s entire human in vivo effector platform within the field of oncology which includes two lead clinical-stage product candidates, one which is in an advanced Phase I study and another which will be the subject of an Investigational New Drug (“IND”) filing during the first half of 2011. ZIOPHARM and Intrexon will host a conference call and audio webcast today, Thursday, January 6th at 5:00 p.m. ET to discuss the global exclusive channel partnership.
Intrexon Appoints Former NIH Investigator to Identify High Value Therapeutic Opportunities
10/7/2010
Germantown, Maryland, October 7, 2010 – Intrexon Corporation, a privately held synthetic biology company, today announced the appointment of William E. Fogler, Ph.D., as Senior Director of Portfolio Analysis and Planning for its Human Therapeutics Division. Dr. Fogler’s efforts will focus on identifying high value therapeutic opportunities for which Intrexon’s proprietary technologies and capabilities confer an unparalleled advantage.
Intrexon Announces Purchase of Industry-Leading Bioassay Operation
9/1/2009
Maryland facility will also be the headquarters of company’s Human Therapeutics Division Blacksburg, Virginia, September 1, 2009 – Intrexon Corporation, a privately held life...